Dynavax Technologies Corporation
Dynavax Technologies — Technical Presentation (October 2018)
36 slides from Dynavax Technologies's technical presentation, Oct 22, 2018
Slide 1: Dynavax: Innovating Immunology
Exhibit 99.3 DYNAVAX INNOVATING IMMUNOLOGY Intro Slide
Slide 2: Background
BACKGROUND Page PD-1 blockade has significantly improved outcomes in advanced melanoma, yet durable responses are elicited in less than half of the patients. There remains an area of unmet need in patients who are anti-PD-1 naïve or experienced. KEYTRUDA® (pembrolizumab) is an anti-PD-1 monoclonal a
Slide 3: Background cont.
BACKGROUND CONT. Page In preclinical studies of anti-PD-1 non-responder mouse tumor models, intratumoral injection of SD-101, in combination with PD-1 blockade, suppressed the growth of tumors at the injected and distant non-injected sites. Wang S, et al., PNAS, 2016. 113(46): p. E7240-e7249 In a pr
Slide 4: Background cont.
BACKGROUND CONT. Page Here, we report the results presented at ESMO from the ongoing phase 2 expansion of SYNERGY-001 in patients with: advanced melanoma resistant/refractory (R/R) to anti-PD-1/L1 therapy; advanced melanoma naïve to anti-PD-1/L1 therapy; and advanced head and neck squamous cell carc
Slide 5: Innate and adaptive immune responses increased by SD-101
BACKGROUND CONT. Page Figure 1. Both Innate and Adaptive Immune Responses Are Increased by Intratumoral Injection of SD-101
Slide 6: Abstract 3781: SD-101 plus pembrolizumab in anti-PD-1 resistant melanoma
Abstract 3781: Phase 1b/2, Open-Label, Multicenter Study of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Advanced Melanoma Resistant/Refractory to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870) A. Ribas1, I. Mehmi2, T. Medina3, C. Lao4, S. Kummar5, A. Amin6,
Slide 7: Methods cont.: Study Design
METHODS CONT. Figure 2. Study Design Combrineet :4 me em ‘$D-101 Weeks cT CT, computed tomography scan Primary Endpoint: Overall response rate assessed by RECIST v1.1 Secondary Endpoints: Safety and tolerability, duration of response, and phenotype of the tumor envi rit *Out of 38 patients, 4 patien
Slide 8: Demographics and Baseline Characteristics
RESULTS Page Characteristics N = 30 Median age, years (Min, Max) 64 (53, 76) Male, n (%) 23 (76.7) ECOG PS 0, n (%) 16 (53.3) Baseline LDH, mean (SD) ≤ULN, n (%) >1 to ≤2 ULN, n (%) >2 ULN, n (%) 223 (3.0, 1886.0) 17 (55%) 9 (29%) 4 (13%) Stage at Screening, n (%) IIIC 10 (33.3) IV 19 (63.3) Missing
Slide 9: Baseline Disease Characteristics
RESULTS CONT. Table 2. Baseline Disease Characteristics Characteristics, n (%) N=30 Prior 6 (20) Prior surgery 28 (93.3) Prior lines of therapy, 1/2/23 11/8/11 PD1/PD-L1 therapy Resistant* 18 (60) Refractory** 12 (40) Prior CTLA-4 therapy 12 (40) * Resistant, progressive disease after a least 3 mont
Slide 10: Efficacy: Best Overall Response
RESULTS CONT. Page Efficacy Table 3. Best Overall Response in mITT by RECIST Best ORR, n (%) N = 29 (mITT*) Objective response rate 6 (20.7) Complete response 1 (3.4) Partial response 5 (17.2) Duration of response (months), median (min, max) 2.1 (1.0, 6.1) Stable disease 5 (17.2) Disease Control Rat
Slide 11: Injected and Non-Injected Lesions
RESULTS CONT. Injected Lesions Patients Non-Injected Lesions Patients ANN vivax.
Slide 12: Injected Lesions
RESULTS CONT. a Injected Lesions weno 80 100 150 «200-250-300 350 8 ANY, DYNAVAX
Slide 13: Patient Response History and Current Status
RESULTS CONT. Figure 5. Patient Response History and Current Status Patients * Complete Reaponse ANN onvax.
Slide 14: Conclusions
CONCLUSIONS Page Preliminary data show encouraging efficacy, with an ORR of 21% Responses were observed in both SD-101 injected and non-injected lesions; however, it is too early to determine the durability of responses The addition of SD-101 to pembrolizumab appears to restore tumor sensitivity to
Slide 15: LBA45: SD-101 plus pembrolizumab in anti-PD-1 naive melanoma
LBA45: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870) G. Long1, M. Milhem2, A. Amin3, C. J. Hoimes4, T. Medina5, R. Conry6, C. Lao7, G. Daniels8
Slide 16: Methods: Phase 1b/2 Trial
METHODS Phase 1b/2 Trial (SYNERGY-001/KEYNOTE-184) Phase 1b Phase 2 Dose Escalation* Dose Expansion SD-101 2 mg i.t. + Pembrolizumab 200 mg i.v. SD-101 2 mg i.t. in up to 4 lesions + SD-101 4 mg i.t. + Pembrolizumab 200 mg iv. Pembrolizumab 200 mg iv. OR SD-101 8 mg i.t. + Pembrolizumab 200 mg i.v.
Slide 17: Demographics and Baseline Characteristics
RESULTS Page Characteristics 2 mg/lesion n = 47 8 mg/lesion n = 40 Median age, years (Min, Max) 66 (36, 85) 66 (33, 89) > 65 years, n (%) 30 (64) 23 (58) Male, n (%) 33 (70) 26 (65) ECOG PS 0, n (%) 30 (64) 30 (75) Baseline LDH, median (Q1, Q3) > ULN, n (%) 193 (162, 234) 8 (17) 195 (177, 238) 10 (2
Slide 18: Safety
RESULTS CONT. Safety Table 2. Safety Summary Eve Any Treatment-related AE Grade 3-4 Chills Myalgia Any irAEs Grade 3-4 ent, N (%) AEs leading to dic of either or both drug n=47 n=40 N=87 43 (91) 37 (93) 80 (92) 12 (26) 16 (40) 28 (32) 4 (9) 1(3) 5 (6) 5 (11) 0 5 (6) 2(4) 3 (8) 5 (6) 4 (9) 2(5) 6 (7)
Slide 19: Efficacy
RESULTS CONT. Efficacy Table 4. Best Overall Response by RECIST v1.1 (ITT Population) 2 mgilesion 8 mgilesion 47 ty) Objective response rate, n (%) [95% Cl] 33 (70) [56, 81] 19 (48) [33, 63] Complete response 5 (11) 2 (5) Partial response 28 (60) 17 (43) Time to response, median (months) 21 23 Durat
Slide 20: Subgroup Analyses Favor 2 mg Dose
Subgroup Analyses Favor 2 mg Dose CI = confidence interval; ECOG = Eastern Cooperative Oncology Group performance status; LDH = lactate dehydrogenase; ORR = objective response rate; RR = risk ratio; ULN = upper limit of normal . 2 mg 8 mg N ORR N ORR RR (95% CI) Overall 47 70% 40 48% 1.5 (1.0. 2.2)
Slide 21: Responses in PD-L1 Negative and Positive Tumors
RESULTS CONT. Table 5. Responses in Both PD-L1 Negative and Positive Tumors 2 mgilesion 8 mg/lesion PD-L1 Expression N ORR (%) N ORR (%) 19 79 13 62 15 80 15 33 Pending/missing 13 46 12 50 = spor rate; PD-L1 tibody Figure 2. Best Percent Change From Baseline in All Target Lesions 120 1 1B 2mgilesion
Slide 22: Duration of Follow Up and Patient Status
RESULTS CONT. Figure 3. Duration of Follow Up and Patient Status 2mgilesion Patients = Partial Response 8 mg/lesion Patients 400 500 600 Days AY 100-200-300
Slide 23: Progression-free Survival (ITT Population)
RESULTS CONT. Figure 5. Progression-free Survival (ITT Population) 10 4 — 2 mgllesion — 8 mgllesion os J + Censored 2 go6 4 g & Bos 4 é 5 & 02 4 oo 4 Log-rank test p = 0.02 T T T T T T 0 5 10 8 20 % Months 2mg 47 24 8 3 2 ° mg 40 23 16 2 1 ° ANN vivax.
Slide 24: Progression-free Survival (ITT Population)
RESULTS CONT. Table 6. Progression-free Survival (ITT Population) 85% (70, 93) 60% (42, 73) 6-month rate (95% Cl) Median (months) (95% Cl) not reached (15.2, NE) 10.4 (4.2, NE) Cl = confidence interval; ITT = intention to treat; NE=not estimable; PFS = progression-free survival ASE ~
Slide 25: Percent Change From Baseline Over Time for Target Lesions
RESULTS CONT. Figure 6. Percent Change From Baseline Over Time for Target Lesions in Patients Who Received 2 mg or 8 mg SD-101 Per Lesion All Injected Target Lesions All Non-injected Target Lesions 140 210 120 120 100 2 mg 100 20 2 60 © 40 40 20 2 ° ° 20 2 ~40 “0 0 0 38 BS & 8 8 & 3 : al 8 a & i g a
Slide 26: Immune-Related Biomarkers
IMMUNE-RELATED BIOMARKERS Page Values above the graphs represent the means and 95% confidence intervals. Methods: biopsies of the injected tumor were collected at screening (prior to dosing) and post-dose. Biopsies were analyzed by the nCounter® PanCancer Immune Profiling Panel (NanoString Technolog
Slide 27: Conclusions
CONCLUSIONS Page The addition of 2 mg/lesion of SD-101 to pembrolizumab appears to increase immune activity in the tumor microenvironment and efficacy compared with 8 mg/lesion in similar patient populations The ORR and PFS were significantly better in the 2 mg/lesion SD-101 group than in the 8 mg/l
Slide 28: Abstract 3560: SD-101 plus pembrolizumab in HNSCC
Abstract 3560: Phase 1b/2, Open-Label, Multicenter Study of Intratumoral SD-101 in Combination With Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT02521870) Ezra Cohen,1 Alain Algazi,2 Douglas Laux,3
Slide 29: Demographics and Baseline Characteristics
RESULTS Page Characteristics 8 mg (n=23) 2 mg (n=10) Median age, years (Min, Max) 65 (43, 91) 60 (38, 84) Male/female sex, % 91/9 50/50 ECOG PS 1, N (%) 22 (84.6) 24 (75.0) Primary tumor location, n (%) Hypopharyngeal 1 (4.3) 1 (10.0) Nasopharyngeal 1 (4.3) 0 Oral 10 (43.4) 4 (40.0) Oropharyngeal 5
Slide 30: Objective Response Rate: SD-101 by dose
RESULTS CONT. Page Table 3. Objective Response Rate: SD-101 8 mg or 2 mg/injection
Slide 31: Injected and Non-Injected Lesions
RESULTS CONT. 140 120 Injected Lesions $100 3 80 @ 60 5 40 3 2 Boo § 20 = -40 8 -60 & -80 -100 0 0 80 100 150 200 250 300 350 Days 140 - - 120 Non-Injected Lesions € 100 3 80 @ 60 — 40 cP) rf 20 § 20 = -40 E -60 -80 -100 0 0) 50 100-Ss:*180« 200 250 300850 IND vivax.
Slide 32: Current Patient Status with SD-101
RESULTS CONT. Figure 4. Current Patient Status with SD-101 8 mg > > > ey ees Gaal rs Cy Cras , | _—_—— £ ¢ |< i rs oo 0. pees a ey eal aaa ————— 4 Partial Response a 4 Stable Disease 4 Progressive Disease a ir =— > Ongoing —> T T T I T T T T 0 50 100 150 200 250 300 350 400 ANN onvax.
Slide 33: HNSCC Conclusions
HNSCC CONCLUSIONS Page The combination therapy showed encouraging efficacy in patients with HNSCC, with an ORR of 27% Median DOR has not been reached. Some prolonged responses Responses observed in both SD-101 injected and non-injected lesions
Slide 34: SD-101 + Pembrolizumab Conclusions
SD-101 + PEMBROLIZUMAB CONCLUSIONS Page Why we think SD-101 adds meaningful clinical benefit to pembrolizumab therapy SD-101 in combination with local low dose radiation induced abscopal responses in 80% of patients with indolent non-Hodgkin’s lymphoma 8 mg of SD-101 induces responses in anti-PD-1/L
Slide 35: Moving Forward
SD-101 + PEMBROLIZUMAB CONCLUSIONS Page Moving forward: Currently recruiting patients to receive 2 mg in 1 to 4 lesions: Advanced melanoma who have tumors that are refractory or resistant to anti-PD-1/L1 therapy Recurrent or metastatic HNSCC with no prior anti-PD-1/L1 therapy
Slide 36: Acknowledgements
ACKNOWLEDGEMENTS Page This study was sponsored by Dynavax Technologies Corporation in collaboration with Merck & Co., Inc., Kenilworth, NJ USA. We thank the patients and their families and caregivers for participating in the study; the participating principal investigators and their study teams; Alb
Dynavax Technologies — Technical Presentation (October 2018) on 6ix